Memory for Action in Neurological Patients

NCT02844855 | Terminated

• 2 other identifiers: 16080682016-A00891-50
• Study Type: interventional
• Target: 83
• Locations: 1 country
• Sites: 2

Brief Summary

Memory for action is especially important in everyday life although current literature is not very abundant. The enactment effect (i.e. better memory for performed actions than for verbally encoded sentences) is usually described as a robust effect in aging and can be found in many diseases. Although the enactment effect has been studied for three decades, there is still no consensus on how it enhances memory. Therefore, in order to gain additional insight into the representational basis of the enactment effect, in the present study, the investigators propose to test neurological patients. The investigators suggested that memory for action should be better than memory for verbally encoded information in Alzheimer's disease and Parkinson's disease. If patients with Alzheimer's disease (AD) and Parkinson's disease (PD) have no cognitive assessment during the last 6 months, then they will realize different tests: MMSE (1), HAD (2), a cognitive assessment (3); (4); BREF (5); Assessment of apraxia, (6). Controls will perform the same tests to verify that they have no cognitive impairment. Then, two experimental conditions will be presented in all patients and controls: a first in which participants will have to name drawings (verbal learning) and a second in which they will have to reproduce an action associated with drawings (action learning). Immediately after this learning phase, a recognition task will be available and therefore participants will have to recognize drawings that had been presented previously. The main criteria used in the statistical analysis will be the correct recognition score.

Conditions

Alzheimer Disease; Parkinson Disease

Keywords

Alzheimer; Parkinson; Action memory

Outcome Measures

Primary Outcomes (1)

• Number of correct answers

  The gain provided by the verbal learning vs action learning (number of correct answers).

  Day 1

Study Arms (3)

patients with Alzheimer disease

ACTIVE COMPARATOR

Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).

Behavioral: Cognitive tests

patients with Parkinson disease

ACTIVE COMPARATOR

Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).

Behavioral: Cognitive tests

healthy controls

SHAM COMPARATOR

Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).

Behavioral: Cognitive tests

Interventions

Cognitive tests BEHAVIORAL

MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).

healthy controls; patients with Alzheimer disease; patients with Parkinson disease

Eligibility Criteria

• Age: 55 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient affiliated to a social security system
• Age between 55 and 80 years
• Normal vision and hearing or successfully corrected
• French mother tongue
• Signature of consent by participants
• Probable AD diagnosis made by a neurologist (McKhann et al., 2011)
• Mini-Mental State Examination (MMSE): score \> 22
• Stable treatment for two months minimum.
• PD diagnosed by a neurologist (Postuma et al., 2015)
• Stable treatment for two months minimum.
• Mini-Mental State Examination (MMSE): score \> 27
• Under dopaminergic treatment

You may not qualify if:

• Other neurological or psychiatric history
• Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD; Zigmond \& Snaith, 1983)
• Inability to communicate
• Significant impairment of judgment
• Delusional or psychotic state
• Other neurological or psychiatric history
• Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD; Zigmond \& Snaith, 1983)
• Inability to communicate
• Significant impairment of judgment
• Delusional or psychotic state
• \- Motor fluctuations
• Psychiatric or neurological disorders
• Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD; Zigmond \& Snaith, 1983)

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Saint Etienne: lead

Study Sites (2)

CHU de Saint-Etienne

Saint-Etienne, 42055, France

Location

Hcl - Cm2R

Villeurbanne, France

Location

MeSH Terms

Conditions

Alzheimer Disease; Parkinson Disease

Interventions

Neuropsychological Tests

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies

Intervention Hierarchy (Ancestors)

Psychological Tests; Behavioral Disciplines and Activities

Study Officials

• Céline BORG, MD

  celine.borg@univ-st-etienne.fr

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 22, 2016
• First Posted: July 26, 2016
• Study Start: December 26, 2016
• Primary Completion: February 21, 2020
• Study Completion: February 21, 2020
• Last Updated: September 17, 2020

Record last verified: 2020-09

Locations

FR (2)